JP2003522160A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003522160A5 JP2003522160A5 JP2001557602A JP2001557602A JP2003522160A5 JP 2003522160 A5 JP2003522160 A5 JP 2003522160A5 JP 2001557602 A JP2001557602 A JP 2001557602A JP 2001557602 A JP2001557602 A JP 2001557602A JP 2003522160 A5 JP2003522160 A5 JP 2003522160A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- vector
- acid sequence
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 description 30
- 239000008194 pharmaceutical composition Substances 0.000 description 28
- 239000013598 vector Substances 0.000 description 25
- 238000000034 method Methods 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 239000004037 angiogenesis inhibitor Substances 0.000 description 15
- 241000701161 unidentified adenovirus Species 0.000 description 15
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 13
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000000508 neurotrophic effect Effects 0.000 description 10
- 210000001508 eye Anatomy 0.000 description 8
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 7
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18174300P | 2000-02-11 | 2000-02-11 | |
| US60/181,743 | 2000-02-11 | ||
| US09/599,997 US6821775B1 (en) | 2000-02-11 | 2000-06-23 | Viral vector encoding pigment epithelium-derived factor |
| US09/599,997 | 2000-06-23 | ||
| US22833700P | 2000-08-28 | 2000-08-28 | |
| US60/228,337 | 2000-08-28 | ||
| PCT/US2001/004203 WO2001058494A2 (en) | 2000-02-11 | 2001-02-09 | Gene therapy for treating ocular-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003522160A JP2003522160A (ja) | 2003-07-22 |
| JP2003522160A5 true JP2003522160A5 (enExample) | 2008-04-10 |
Family
ID=27391455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001557602A Pending JP2003522160A (ja) | 2000-02-11 | 2001-02-09 | 眼関連疾患の治療のための遺伝子治療 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1253948A2 (enExample) |
| JP (1) | JP2003522160A (enExample) |
| AU (1) | AU780634C (enExample) |
| CA (1) | CA2398571A1 (enExample) |
| WO (1) | WO2001058494A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7470659B2 (en) | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
| AU2003297607A1 (en) * | 2002-12-02 | 2004-06-23 | Genvec, Inc | Materials and methods for treating ocular-related disorders |
| US20040166091A1 (en) * | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
| CA2588093A1 (en) | 2004-11-16 | 2006-05-26 | Rony Seger | Variants of pigment epithelium derived factor and uses thereof |
| WO2006123248A2 (en) * | 2005-04-18 | 2006-11-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject |
| JP2007291009A (ja) * | 2006-04-25 | 2007-11-08 | Seitai Shigen Laboratory Inc | 血管内膜肥厚抑制剤 |
| WO2009126894A2 (en) * | 2008-04-11 | 2009-10-15 | Massachusetts Eye And Ear Infirmary | Methods and compositions for the diagnosis and treatment of angiogenic disorders |
| EP3369747A1 (en) * | 2012-06-25 | 2018-09-05 | The Brigham and Women's Hospital, Inc. | Targeted theratpeutics |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| US10385112B2 (en) | 2013-03-14 | 2019-08-20 | Asklepios Biopharmaceutical, Inc. | Modified soluble VEGF receptor-1 genes and vectors for gene therapy |
| TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
| US12305185B2 (en) | 2018-01-23 | 2025-05-20 | Mount Spec Investments Pty Ltd | Expression vector and method |
| KR102785135B1 (ko) | 2018-06-11 | 2025-03-21 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 눈 질환을 치료하는 탈메틸화 |
| CA3104472C (en) * | 2018-06-19 | 2025-12-16 | Cella Therapeutics, Llc | Drug delivery systems comprising active pharmaceutical ingredients and a sustained delevery component |
| AU2019288296B2 (en) * | 2018-06-19 | 2022-11-24 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
| JP7769388B2 (ja) | 2019-12-12 | 2025-11-13 | ティン セラピューティクス，インコーポレイテッド | 聴覚損失の予防及び治療のための組成物及び方法 |
| KR20220118499A (ko) * | 2019-12-18 | 2022-08-25 | 셀라 테라퓨틱스, 엘엘씨 | 신경영양제, 세포자멸 신호전달 단편 억제제(FAS) 또는 FAS 리간드(FASL) 억제제, 종양 괴사 인자-α(TNF-α) 또는 TNF 수용체 억제제, 미토콘드리아 펩티드, 올리고뉴클레오티드, 케모카인 억제제 또는 시스테인-아스파틱 프로테아제 억제제를 포함하는 약물 전달 시스템 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840686A (en) * | 1992-09-24 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use |
| US6319687B1 (en) * | 1992-09-24 | 2001-11-20 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene |
| US5461749A (en) * | 1994-05-31 | 1995-10-31 | Minnesota Mining And Manufacturing Company | Floor mop and cleaning system |
| US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
| JP2001510804A (ja) * | 1997-07-23 | 2001-08-07 | ノースウエスタン・ユニバーシテイ | 血管新生を阻害するための方法及び組成物 |
| CA2304173A1 (en) * | 1997-09-23 | 1999-04-01 | Genvec, Inc. | Plasmids for construction of eukaryotic viral vectors |
| WO1999026480A1 (en) * | 1997-11-20 | 1999-06-03 | Genetix Pharmaceuticals, Inc. | Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases |
| AU3755900A (en) * | 1999-03-15 | 2000-10-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
-
2001
- 2001-02-09 JP JP2001557602A patent/JP2003522160A/ja active Pending
- 2001-02-09 WO PCT/US2001/004203 patent/WO2001058494A2/en not_active Ceased
- 2001-02-09 EP EP01909022A patent/EP1253948A2/en not_active Withdrawn
- 2001-02-09 CA CA002398571A patent/CA2398571A1/en not_active Abandoned
- 2001-02-09 AU AU36818/01A patent/AU780634C/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peng et al. | Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases | |
| JP2003522160A5 (enExample) | ||
| Seal et al. | Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues | |
| Yuan et al. | Ocular drug delivery nanowafer with enhanced therapeutic efficacy | |
| Grewal et al. | Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy: a pilot study | |
| Bandello et al. | Pathophysiology and treatment of diabetic retinopathy | |
| Miller et al. | Regression of experimental iris neovascularization with systemic alpha-interferon | |
| US7989426B2 (en) | Selective induction of apoptosis to treat ocular disease by expression of PEDF | |
| US20030045498A1 (en) | Materials and methods for treating ocular-related disorders | |
| JP2017061467A5 (enExample) | ||
| US20090041759A1 (en) | Materials and methods for treating ocular-related disorders | |
| Thanos et al. | Delivery of neurotrophic factors and therapeutic proteins for retinal diseases | |
| WO2008137066A1 (en) | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases | |
| Barros et al. | The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea | |
| US20110142923A1 (en) | Ophthalmic pharmaceutical compositions for the treatment of neoangiogenic pathologies of the eye | |
| KR102307421B1 (ko) | 다중 키나아제 억제제 및 안구 섬유증에의 사용 | |
| AU780634B2 (en) | Gene Therapy for treating ocular-related disorders | |
| CN114845718A (zh) | 用于治疗与过度血管形成相关的眼部疾病的化合物 | |
| US7943590B2 (en) | Compositions and methods for treating ophthalmic disorders | |
| Ichhpujani et al. | Bevacizumab in glaucoma: a review | |
| Kuo et al. | Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis | |
| WO1999024056A1 (en) | Regulation of ocular angiogenesis | |
| WO2006055947A2 (en) | Methods of regulating angiogenesis through stabilization of pedf | |
| US20030170209A1 (en) | Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization | |
| Rasmussen et al. | Looking into anti-angiogenic gene therapies for disorders of the eye |